We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Democrats in both the House and Senate have penned letters to the Department of Justice protesting its $8.3 billion settlement with Purdue Pharma that would see the beleaguered opioid maker become a public benefit company as it emerges from bankruptcy over its role in the opioid crisis. Read More
The Infectious Diseases Society of America (IDSA) said that it is conducting its own evaluation of the data that led to the FDA’s Emergency Use Authorization (EUA) for the 700-mg dose of Eli Lilly’s COVID-19 antibody treatment bamlanivimab. Read More
Research into COVID-19 therapeutics has faced a number of problems during the pandemic that ought to be learned from, including underpowered trials, a lack of coordination and enrollment issues, according to Center for Drug Evaluation and Research (CDER) Director Janet Woodcock, who is currently on leave heading the therapeutics arm of the government’s Operation Warp Speed program. Read More
A United Nations-backed agency announced yesterday that 18 generic drug manufacturers have pledged to cooperate to speed up access to COVID-19 treatments for low- and middle-income countries. Read More
Mallinckrodt has launched a retrospective study to collect real-world data on its nitric gas inhaled therapy, INOmax, as a potential treatment for COVID-19 patients with respiratory problems. Read More
Novavax published its entire $1.6 billion Operation Warp Speed vaccine contract in a Securities and Exchange Commission (SEC) filing this week, ending speculation about the details. Read More
The World Health Organization (WHO)’s ACT-Accelerator program is focusing on increasing global access to dexamethasone and monoclonal antibodies and has built up significant vaccine manufacturing capabilities, but it has zero plans for facilitating access to the only FDA-approved COVID-19 treatment, remdesivir. Read More